Wordt geladen...
A147 COMBINING INFLIXIMAB TROUGH LEVELS AND FECAL CALPROTECTIN LEVELS WITH CLINICAL DATA HAS THE POTENTIAL TO GUIDE CLINICAL DECISION-MAKING IN IMPROVING OUTCOMES FOR INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE INFLIXIMAB.
BACKGROUND: Infliximab (IFX) induces and maintains remission in Crohn’s Disease (CD) and Ulcerative Colitis (UC). Secondary loss of response occurs in up to 45% of CD and 60% of UC patients on maintenance IFX. Studies are inconclusive on ideal IFX trough levels (ITLs) to prevent loss of response; re...
Bewaard in:
| Gepubliceerd in: | J Can Assoc Gastroenterol |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Oxford University Press
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6507628/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.148 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|